Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| See historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Fell Below 200 DMA | Bearish | -0.55% | |
| Fell Below 20 DMA | Bearish | -0.55% | |
| Fell Below 50 DMA | Bearish | -0.55% | |
| 180 Bearish Setup | Bearish Swing Setup | -0.55% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | -0.55% | |
| Wide Range Bar | Range Expansion | -0.55% | |
| Multiple of Ten Bearish | Other | -0.55% | |
| Wide Bands | Range Expansion | -0.55% | |
| Crossed Above 50 DMA | Bullish | -12.77% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Medicine Biopharmaceutical Cancer Chemical Compounds Oncology Solid Tumors Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Medicine Biopharmaceutical Cancer Chemical Compounds Oncology Solid Tumors Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 111.99 |
| 52 Week Low | 30.76 |
| Average Volume | 555,805 |
| 200-Day Moving Average | 80.3275 |
| 50-Day Moving Average | 83.6324 |
| 20-Day Moving Average | 78.1455 |
| 10-Day Moving Average | 77.541 |
| Average True Range | 4.5664 |
| ADX | 17.29 |
| +DI | 25.185 |
| -DI | 30.5507 |
| Chandelier Exit (Long, 3 ATRs ) | 82.1808 |
| Chandelier Exit (Short, 3 ATRs ) | 83.1992 |
| Upper Bollinger Band | 89.3995 |
| Lower Bollinger Band | 66.8915 |
| Percent B (%b) | 0.4 |
| BandWidth | 28.802682 |
| MACD Line | -1.8196 |
| MACD Signal Line | -2.4981 |
| MACD Histogram | 0.6785 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.9 Billion |
| Num Shares | 25 Million |
| EPS | -3.38 |
| Price-to-Earnings (P/E) Ratio | -22.47 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 3.81 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 80.09 | ||||
| Resistance 3 (R3) | 79.90 | 78.33 | 79.40 | ||
| Resistance 2 (R2) | 78.33 | 77.28 | 78.43 | 79.17 | |
| Resistance 1 (R1) | 77.14 | 76.62 | 76.36 | 77.33 | 78.94 |
| Pivot Point | 75.57 | 75.57 | 75.18 | 75.67 | 75.57 |
| Support 1 (S1) | 74.38 | 74.52 | 73.60 | 74.57 | 72.96 |
| Support 2 (S2) | 72.81 | 73.86 | 72.91 | 72.73 | |
| Support 3 (S3) | 71.62 | 72.81 | 72.50 | ||
| Support 4 (S4) | 71.81 |
